For bipolar affective disorder, diagnosis and treatment has long been in the shadow of that of schizophrenia. Bipolar disorder is often seen as a less serious condition and one for which satisfactory treatments have long existed. The reality belies this perception, for example more acute beds are occupied at any given moment in the NHS by bipolar patients than sufferers of schizophrenia.
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A review of medication charts for patients with bipolar disorder often reveals a mix of polypharmacy for which little systematic evidence exists. It was with a view to providing a clearer prescribing pathway and rationale that the BAP published guidelines for the treatment of bipolar disorder 3 years ago. These guidelines were broadly welcomed, but drew attention to the relative paucity of studies supporting even some of the treatments for acute mania. Even less data exist to guide the clinician in the arena of maintenance and prophylaxis. Since the BAP guidelines, other guidelines have been generated. It is against this backdrop that the Newcastle group was convened. The objective of the meeting was to review the impact of new evidence, to address the issue of clinical therapeutic uncertainty in the period after resolution of the symptoms of acute mania, to review data indicating the best strategies for maintenance and to provide the best advice for maintenance and relapse prevention.
The group discussed data giving a historical perspective to treatment, beginning with the use of lithium. While early experiences suggested a good response to this treatment, subsequent follow up studies were less optimistic for long-term improvement of outcome. Yet the perception of the efficacy of lithium as a defining treatment for mania and bipolar disorder has been influential in the prognosis of this condition.
While practitioners should take heed of the therapeutic evidence base, it is important to recognize the limitations of the data base in the area of maintenance and prophylaxis in bipolar disorder. Guidelines must inform rather than constrict clinicians. Equally, it is important to recognize that even using the best information available, the prognosis for bipolar disorder remains poor. Therapeutic nihilism should never be permitted, but at the same time it is necessary to recognize the limitations of the current therapeutic interventions available to us. Humility on the part of the clinician and an appreciation of the devastating and debilitating impact of this condition on the lives of sufferers should never be forgotten. It is also clear from these papers that much research remains to be done. Greater knowledge of the nature and course of the illness and of the role of psychological and physical treatments will enhance the treatment of bipolar disorder in the future.
